A detailed history of Wells Fargo & Company transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 26,120 shares of TERN stock, worth $148,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,120
Previous 25,081 4.14%
Holding current value
$148,361
Previous $170,000 27.65%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.49 - $10.8 $6,743 - $11,221
1,039 Added 4.14%
26,120 $217,000
Q2 2024

Aug 13, 2024

BUY
$4.54 - $8.2 $50,048 - $90,396
11,024 Added 78.42%
25,081 $170,000
Q1 2024

May 10, 2024

BUY
$4.86 - $8.19 $9,734 - $16,404
2,003 Added 16.62%
14,057 $92,000
Q4 2023

Feb 09, 2024

BUY
$3.37 - $6.86 $8,654 - $17,616
2,568 Added 27.07%
12,054 $78,000
Q3 2023

Nov 13, 2023

SELL
$4.7 - $8.55 $36,786 - $66,920
-7,827 Reduced 45.21%
9,486 $47,000
Q2 2023

Aug 15, 2023

BUY
$7.35 - $13.29 $125,714 - $227,312
17,104 Added 8183.73%
17,313 $151,000
Q1 2023

May 12, 2023

BUY
$7.91 - $12.0 $656 - $996
83 Added 65.87%
209 $2,000
Q4 2022

Feb 13, 2023

BUY
$4.62 - $10.18 $18 - $40
4 Added 3.28%
126 $1,000
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $130 - $449
70 Added 134.62%
122 $1,000
Q2 2022

Aug 12, 2022

SELL
$1.5 - $3.0 $841 - $1,683
-561 Reduced 91.52%
52 $0
Q1 2022

May 16, 2022

SELL
$2.83 - $6.7 $13,770 - $32,602
-4,866 Reduced 88.81%
613 $2,000
Q4 2021

Feb 14, 2022

BUY
$5.65 - $10.73 $30,871 - $58,628
5,464 Added 36426.67%
5,479 $39,000
Q3 2021

Nov 15, 2021

BUY
$7.22 - $13.46 $108 - $201
15 New
15 $0
Q2 2021

Aug 16, 2021

SELL
$12.26 - $22.0 $33,273 - $59,708
-2,714 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$17.13 - $27.25 $46,490 - $73,956
2,714 New
2,714 $60,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $214M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.